特集論文
島津評論 80〔3・4〕 115～124 (2023)
要旨
Dihydropyrimidine dehydrogenase is well known as the conversion of Uracil to Dihydrouracil and is the major pathway for the detoxification of 5-fluorouracil (5-FU). 5-FU is major anti-cancer drug in the world but patients with DihydroPyrimidine Dehydrogenase (DPD) deficiency accumulate 5-FU and show severe side effect, until the death of patients in certain cases. However, only genetic testing kit is commercially available but there is none for analysis based on the phenotype. Genetic testing kit can check only some targeted gene mutation and cannot detect any other modification affecting on the DPD activity. To solve this issue, DOSIURA kit for LC-MS/MS was developed in order to evaluate the DPD activity by direct measurement of Uracil and Dihydrouracil. DOSIURA kit is a ready-to-use kit which means that it includes all the component to perform LC-MS/MS analysis. In this study, the method validation result such as precision, accuracy, sensitivity, and signal stability are described, and the results show that DOSIURA kit has good analytical performance to measure the DPD activity by directly measuring of the amount of Uracil and Dihydrouracil.
1Clinical and Microbiological Testing Business Unit, Diagnostic management department, Analytical & Measuring Instrument Division, Shimadzu corporation, Kyoto, Japan
2Alsachim SAS, Strasbourg, France
＊島津評論に掲載されている情報は、論文発表当時のものです。記載されている製品は、既に取り扱っていない場合もございますので、ご了承ください。